Clorox (NYSE: CLX) saw its shares advance in after-hours trading on Monday after the company issued a fiscal 2027 sales growth forecast that exceeded Wall Street expectations, though a closer look reveals that most of the projected expansion stems from one-off factors rather than robust underlying demand.
The cleaning and household products giant projected sales growth of 13% to 14% for fiscal 2027, comfortably above the 12.8% consensus estimate compiled by LSEG. The stock closed the regular session up 2.86% at $98.26 and tacked on an additional 0.56% after the bell.
However, the headline number masks a more modest reality. According to company figures, approximately 96% of the midpoint growth is attributable to the recently acquired GOJO business and favorable comparisons related to last year's ERP system implementation. The GOJO acquisition alone contributes roughly 9.5 percentage points to the 13.5% midpoint, while the ERP comparison benefit adds more than 3.5 points. Excluding these items, underlying organic growth is less than half a percentage point.
The profit outlook also appears softer than anticipated. Clorox guided adjusted earnings for fiscal 2027 to approximately $5.85 per share, about 2% below the $5.97 LSEG estimate. The company expects gross margin to hover near 42%, slightly down from the 42.3% projected for fiscal 2026. Management cited persistent inflation and an unfavorable product mix as headwinds that would offset cost-saving initiatives.
The fourth-quarter results, released alongside the guidance, beat Wall Street's reduced expectations but showed significant margin pressure. Net sales came in at $1.95 billion, down 2% year-over-year but roughly 2.6% above the $1.90 billion consensus. Adjusted EPS of $1.66 beat by a penny, yet that represented a 42% decline from the prior year. Gross margin contracted by 520 basis points to 41.3%, with ERP timing and GOJO inventory accounting each shaving off approximately 150 basis points.
Segment performance was mixed. Health and Wellness saw a 16% net sales increase, driven by GOJO's roughly 28-point contribution, but adjusted EBIT fell 15%. Household and Lifestyle segments both experienced double-digit sales declines, down 18% and 17% respectively, with adjusted EBIT plunging 56% and 60%. International was the bright spot, posting 4% sales growth and a 17% increase in adjusted EBIT, helped by currency tailwinds and cost savings.
On Monday, Clorox outperformed several consumer staples and sanitation peers. The stock rose 2.86%, while Procter & Gamble (PG) gained just 0.33%, Ecolab (ECL) added 0.65%, and Colgate-Palmolive (CL) fell 1.56%. Despite the bounce, Clorox shares remain down 2.05% over the past five sessions, with Monday's gain only partially offsetting last week's decline.
Investors will also note the upcoming dividend record date of August 12, with the increased quarterly dividend of $1.25 payable on August 28. The stock's dividend yield stands at approximately 5.2%, but the slim earnings cushion raises questions about payout sustainability.
Chief Executive Linda Rendle characterized the environment as "challenging," citing "continued cost volatility and a value-seeking consumer." The unchanged margin forecast reflects that cautious stance. Meanwhile, the company continues its search for a new CEO, adding leadership uncertainty during the integration of the $2.25 billion GOJO acquisition, which could pressure execution and margins in the near term.
